CD274 and melanoma: While these results place EXO‐PD‐L1 in a category of promising biomarkers for melanoma and other cancer types, the tumour origin of EXO‐PD‐L1 remains speculative, as they were not validated TEX and might have largely originated from non‐malignant PD‐L1+ cells.